<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MSL WORLD BLOG</title>
	<atom:link href="http://www.mslworld.com/blog/?feed=rss2" rel="self" type="application/rss+xml" />
	<link>http://www.mslworld.com/blog</link>
	<description>Medical Science Liaison World-All free career resources for the Medical Science Liaison role</description>
	<lastBuildDate>Fri, 17 May 2013 16:13:47 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>EMA says Bayer&#8217;s Diane-35 has more benefit than risk</title>
		<link>http://www.mslworld.com/blog/?p=42862</link>
		<comments>http://www.mslworld.com/blog/?p=42862#comments</comments>
		<pubDate>Fri, 17 May 2013 16:13:47 +0000</pubDate>
		<dc:creator>Dr. Samuel Dyer</dc:creator>
				<category><![CDATA[Pharma Industry Business News]]></category>
		<category><![CDATA[acne-treatment]]></category>
		<category><![CDATA[agency]]></category>
		<category><![CDATA[bayer]]></category>
		<category><![CDATA[contraceptives]]></category>
		<category><![CDATA[diane-35]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drug-regulator]]></category>
		<category><![CDATA[ema]]></category>
		<category><![CDATA[european]]></category>
		<category><![CDATA[european-medicines]]></category>
		<category><![CDATA[france]]></category>
		<category><![CDATA[insisted-the-european]]></category>
		<category><![CDATA[its-off-label]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medical-liaison]]></category>
		<category><![CDATA[regulatory]]></category>
		<category><![CDATA[sales and marketing]]></category>
		<category><![CDATA[the-drug]]></category>
		<category><![CDATA[the-off-label]]></category>
		<category><![CDATA[“msl jobs”]]></category>

		<guid isPermaLink="false">http://www.mslworld.com/blog/?p=42862</guid>
		<description><![CDATA[ France drug regulator in January yanked Bayer&#39;s contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use. ]]></description>
		<wfw:commentRss>http://www.mslworld.com/blog/?feed=rss2&#038;p=42862</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EMA says Bayer&#8217;s Diane-35 has more benefit than risk</title>
		<link>http://www.mslworld.com/blog/?p=42861</link>
		<comments>http://www.mslworld.com/blog/?p=42861#comments</comments>
		<pubDate>Fri, 17 May 2013 16:13:47 +0000</pubDate>
		<dc:creator>Dr. Samuel Dyer</dc:creator>
				<category><![CDATA[Pharma Industry Business News]]></category>
		<category><![CDATA[agency]]></category>
		<category><![CDATA[bayer]]></category>
		<category><![CDATA[contraceptives]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[drug-regulator]]></category>
		<category><![CDATA[ema]]></category>
		<category><![CDATA[european]]></category>
		<category><![CDATA[european-medicines]]></category>
		<category><![CDATA[france]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[sales and marketing]]></category>
		<category><![CDATA[the-drug]]></category>

		<guid isPermaLink="false">http://www.mslworld.com/blog/?p=42861</guid>
		<description><![CDATA[ France drug regulator in January yanked Bayer&#39;s contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use. ]]></description>
		<wfw:commentRss>http://www.mslworld.com/blog/?feed=rss2&#038;p=42861</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK tries novel approach in emerging markets: price cuts</title>
		<link>http://www.mslworld.com/blog/?p=42864</link>
		<comments>http://www.mslworld.com/blog/?p=42864#comments</comments>
		<pubDate>Fri, 17 May 2013 15:41:53 +0000</pubDate>
		<dc:creator>Dr. Samuel Dyer</dc:creator>
				<category><![CDATA[Pharma Industry Business News]]></category>
		<category><![CDATA[build-its]]></category>
		<category><![CDATA[cfo]]></category>
		<category><![CDATA[china]]></category>
		<category><![CDATA[emerging-markets]]></category>
		<category><![CDATA[glaxosmithkline]]></category>
		<category><![CDATA[gsk]]></category>
		<category><![CDATA[mainstays]]></category>
		<category><![CDATA[msl world]]></category>
		<category><![CDATA[retail-works]]></category>
		<category><![CDATA[simon]]></category>
		<category><![CDATA[simon-dingemans]]></category>
		<category><![CDATA[the-mainstays]]></category>

		<guid isPermaLink="false">http://www.mslworld.com/blog/?p=42864</guid>
		<description><![CDATA[ GlaxoSmithKline CFO Simon Dingemans?has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale. ]]></description>
		<wfw:commentRss>http://www.mslworld.com/blog/?feed=rss2&#038;p=42864</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
